Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 34, 2015, Pages 10786-10791

  Ågerstam, Helena ^a   Karlsson, Christine ^a   Hansen, Nils ^a   Sandén, Carl ^a   Askmyr, Maria ^a   Von Palffy, Sofia ^a   Högberg, Carl ^a   Rissler, Marianne ^a   Wunderlich, Mark ^b   Juliusson, Gunnar ^c   Richter, Johan ^c   Sjöström, Kjell ^d   Bhatia, Ravi ^e   Mulloy, James C ^b   Järås, Marcus ^a   Fioretos, Thoas ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF CINCINNATI   (United States)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d Innovagen AB   (Sweden)

^e Heerskink School of Medicine   (United States)

Author keywords

AML; Antibody; IL1RAP; Immunotherapy; Leukemia

Indexed keywords

ANTILEUKEMIC AGENT; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3F8; MONOCLONAL ANTIBODY 81.2; STAUROSPORINE; UNCLASSIFIED DRUG; IL1RAP PROTEIN, HUMAN; TUMOR PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ANTILEUKEMIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL KILLING; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EFFECTOR CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THERAPY EFFECT; TREATMENT RESPONSE; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL DIVISION; CYTOTOXICITY; DRUG SCREENING; IMMUNOLOGY; LEUKEMIA, MYELOID, ACUTE; NONOBESE DIABETIC MOUSE; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL DIVISION; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; INTERLEUKIN-1; INTERLEUKIN-1 RECEPTOR ACCESSORY PROTEIN; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84940544514     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1422749112     Document Type: Article

References (38)

1. Cancer Genome Atlas Research Network (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368(22):2059-2074.
2. Burnett A, Wetzler M, Löwenberg B (2011) Therapeutic advances in acute myeloid leukemia. J Clin Oncol 29(5):487-494.
3. Hope KJ, Jin L, Dick JE (2004) Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 5(7): 738-743.
4. Ishikawa F, et al. (2007) Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 25(11):1315-1321.
5. Hoelzer D (2013) Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia. Curr Opin Oncol 25(6):701-706.
6. Jackson SE, Chester JD (2015) Personalised cancer medicine. Int J Cancer 137(2): 262-266.
7. Subramaniam S, Stansberg C, Cunningham C (2004) The interleukin 1 receptor family. Dev Comp Immunol 28(5):415-428.
8. Järås M, et al. (2010) Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc Natl Acad Sci USA 107(37):16280-16285.
9. Askmyr M, et al. (2013) Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. Blood 121(18):3709-3713.
10. Barreyro L, et al. (2012) Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood 120(6):1290-1298.
11. Wunderlich M, et al. (2010) AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia 24(10):1785-1788.
12. Ohanian M, et al. (2013) Is acute myeloid leukemia a liquid tumor? Int J Cancer 133(3): 534-543.
13. Theocharides APA, et al. (2012) Disruption of SIRPα signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts. J Exp Med 209(10): 1883-1899.
14. Wunderlich M, et al. (2013) AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model. Blood 121(12):e90-e97.
15. Sakai K, et al. (1987) Autocrine stimulation of interleukin 1 beta in acute myelogenous leukemia cells. J Exp Med 166(5):1597-1602.
16. Cozzolino F, et al. (1990) Interleukin-1 and interleukin-2 control granulocyte- and granulocyte-macrophage colony-stimulating factor gene expression and cell proliferation in cultured acute myeloblastic leukemia. Int J Cancer 46(5):902-907.
17. Cozzolino F, et al. (1989) Interleukin 1 as an autocrine growth factor for acute myeloid leukemia cells. Proc Natl Acad Sci USA 86(7):2369-2373.
18. Delwel R, et al. (1989) Interleukin-1 stimulates proliferation of acute myeloblastic leukemia cells by induction of granulocyte-macrophage colony-stimulating factor release. Blood 74(2):586-593.
19. Bradbury D, Bowen G, Kozlowski R, Reilly I, Russell N (1990) Endogenous interleukin-1 can regulate the autonomous growth of the blast cells of acute myeloblastic leukemia by inducing autocrine secretion of GM-CSF. Leukemia 4(1):44-47.
20. Rambaldi A, et al. (1991) Modulation of cell proliferation and cytokine production in acute myeloblastic leukemia by interleukin-1 receptor antagonist and lack of its expression by leukemic cells. Blood 78(12):3248-3253.
21. Rambaldi A, Torcia M, Dinarello CA, Barbui T, Cozzolino F (1993) Modulation of cell proliferation and cytokine production in AML by recombinant interleukin-1 receptor antagonist. Leukemia 7(Suppl 2):S10-S12.
22. Estrov Z, et al. (1992) Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors. Blood 79(8):1938-1945.
23. Stosić-Grujicić S, Basara N, Milenković P, Dinarello CA (1995) Modulation of acute myeloblastic leukemia (AML) cell proliferation and blast colony formation by antisense oligomer for IL-1 beta converting enzyme (ICE) and IL-1 receptor antagonist (IL-1ra). J Chemother 7(1):67-70.
24. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE (2006) Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12(10):1167-1174.
25. Majeti R, et al. (2009) CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138(2):286-299.
26. Jin L, et al. (2009) Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 5(1): 31-42.
27. Kikushige Y, et al. (2010) TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell 7(6):708-717.
28. He SZ, et al. (2015) A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia. Leuk Lymphoma 56(5):1406-1415.
29. Le Jeune C, Thomas X (2015) Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia. Eur J Haematol 94(2):99-108.
30. Weng W-K, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21(21):3940-3947.
31. Musolino A, et al. (2008) Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26(11):1789-1796.
32. Bibeau F, et al. (2009) Impact of FcgammaRIIa-FcgammaRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 27(7):1122-1129.
33. Nimmerjahn F, Ravetch JV (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8(1):34-47.
34. Cartron G, et al. (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99(3): 754-758.
35. Vidriales MB, et al. (1993) Lymphoid subsets in acute myeloid leukemias: Increased number of cells with NK phenotype and normal T-cell distribution. Ann Hematol 67(5):217-222.
36. Bryceson YT, March ME, Ljunggren H-G, Long EO (2006) Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev 214:73-91.
37. Costello RT, et al. (2002) Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 99(10):3661-3667.
38. Agarwal A, et al. (2014) Targeted suppression of interleukin-1 signaling inhibits growth of primary human acute myeloid leukemia cells. Cancer Res 74(19 Suppl): abstr 5248.